How does Eisai justify its existence?

[Anonymous]

No innovation, no new products, no real talent, no morale, no clear plan for the future.

 

[Anonymous]

No innovation, no new products, no real talent, no morale, no clear plan for the future.

And you point is???? Anyone left at eisai can't get another job so they're stuck.

 

[Anonymous]

Some of us are just waiting for pay-day!

 

[Anonymous]

Close to 4 billion in gross sales justifies our existence dickwad.

 

[Anonymous]

It can't. It's a sh!t show.

 

[Anonymous]

Tic-toc.

 

[Anonymous]

Close to 4 billion in gross sales justifies our existence dickwad.

$4 billion? What is this, 2009?

 

[Anonymous]

$4 billion? What is this, 2009?

They're sleepwalking again. Shhhh, you'll wake them up!

 

[Anonymous]

No innovation, no new products, no real talent, no morale, no clear plan for the future.

Eisai's hii reality

Hypocrisy, Incompetence, Insincerity

 

[Anonymous]

Not exactly a stampede of people rushing to defend the company.

 

[Anonymous]

The dwindling #'s (revenue, IC payouts) and non-existent pipeline speak for themselves. If you're the last one out, please don't forget the lights.

 

[Anonymous]

100 Tice Blvd. will be a target store by 2013.

 

[Anonymous]

100 Tice Blvd. will be a target store by 2013.

That's funny!

 

[Anonymous]

The dwindling #'s (revenue, IC payouts) and non-existent pipeline speak for themselves. If you're the last one out, please don't forget the lights.

And the Flag! But not that one with the big red zero on it!

 

[Anonymous]

so what is it now? a tax write-off for Azi Japan?

 

[Anonymous]

so what is it now? a tax write-off for Azi Japan?

Over several hundred million invested in plant and equipment over the years that they have no use for now.

 

[Anonymous]

Through dumb luck, Eisai was able to stumble upon two drugs with blockbuster potential. They were smart enough to hitch their wagon to market leading companies to help build those brands, so they should be given kudos for that. The vast majority of the success was solely due to the efforts of Pfizer and J&J. On the rare occasion when Eisai was able to influence a key decision, it was invariably a royal f up (e.g. the pricing strategy for Aciphex, etc.). Since then, not one successful move has been made in 10 years. Business development is the worst underperfomer, but every part of the business has failed miserably. The company now needs to content itself with a gradual settling to a $400 million - $500 million revenue base in the U.S. generated by a portfolio of ancient products in genericized markets, continued cost cutting, focus on throughput and efficiency, and 10% margins. There really are no other options, resources, talent or leadership, which could change that inevitability. It'll be a long, cold winter.